

Electronic Acknowledgement Receipt

EFS ID:	7218395
Application Number:	09776936
International Application Number:	
Confirmation Number:	8682
Title of Invention:	INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS
First Named Inventor/Applicant Name:	Scott Miller
Correspondence Address:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I Suite 1400 2200 Clarendon Boulevard Arlington VA 22201 US 7032436333 -
Filer:	Csaba Henter/Ashley Weber
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 6 P1
Receipt Date:	16-MAR-2010
Filing Date:	22-DEC-1998
Time Stamp:	17:27:17
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
File Listing:	

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	DE3529247.pdf	1704794	no	79
			129d9dfeeb07c5dc13d1481c17b0e4eb94816c		
Warnings:					
Information:					
2	Foreign Reference	wo90002112.pdf	3129308	no	86
			22a520a51a9e9f1a5a116b62a238ce1dfeba947		
Warnings:					
Information:					
3	Foreign Reference	wo97009973.pdf	10741786	no	318
			f13b5f98b981ff8d00a7be00cc0bc0625488c05c		
Warnings:					
Information:					
4	Foreign Reference	wo98020868.pdf	1853580	no	34
			895525b7f10e0e061a15581e0c23d802b78758		
Warnings:					
Information:					
5	Foreign Reference	wo98045268.pdf	7723932	no	200
			527d2e36d8ff9c2bd22742e57c1525436324efe		
Warnings:					
Information:					
6	Foreign Reference	wo99028305.pdf	6416654	no	161
			901989445d31e040c4e444913bc91f72899856		
Warnings:					
Information:					
7	Foreign Reference	wo00043366.pdf	8008880	no	208
			711871cd9ae232343d56100b737375800ceaa653		
Warnings:					
Information:					
8	Foreign Reference	wo00056331.pdf	3362651	no	89
			4b2874617a6c78d33829e9593de7d6c4178a78b		
Warnings:					
Information:					
9	Foreign Reference	wo02014331.pdf	1459197	no	38
			83086d4df02fce100bae45c1bcb0ef380dc6f07		

Warnings:					
Information:					
10	Foreign Reference	WO020627630.pdf	5208168 date7b1bf3baf5c53da3b0d094e05d91097c0ba0	no	125
Warnings:					
Information:					
11	Foreign Reference	WO02083628.pdf	5772871 b51b4865c60946fa30bd1114a91207a964c07ba0	no	155
Warnings:					
Information:					
12	Foreign Reference	wo02085857.pdf	2888772 a3f554efbcbade0947110f0bed421ee76f0c0b09	no	65
Warnings:					
Information:					
13	Foreign Reference	wo02085859.pdf	4355339 730c606c112b3ae7801571ee592c0da0600ee01	no	97
Warnings:					
Information:					
14	Foreign Reference	WO02092576.pdf	2861903 db0b67417074630a5536215d8aa76323e1113b	no	67
Warnings:					
Information:					
15	Foreign Reference	EP0690344.pdf	1542518 a130ba0bb66c48ae72967d15fbb0b06a655055cb	no	55
Warnings:					
Information:					
16	NPL Documents	AdjeiAPhaseIStudyofBAY439006andGefitinibinPatientswithAREfractory.pdf	69532 a79d8799ac7d476573805e74bd8017a219a4a	no	1
Warnings:					
Information:					
17	NPL Documents	AhmadKinaseInhibitionwithBAY439006inRenalCellCarcinoma.pdf	590309 da2ba12065e158558c23345c35aaf18d82c0810	no	5
Warnings:					
Information:					
18	NPL Documents	AUCLAIRETAL.pdf	59931 57e7cbe3fca9f0331d09b04f1b297a7a02c0c	no	1

Warnings:					
Information:					
19	NPL Documents	BANKSTONDETAL.pdf	365909 be97be697a5dfac6470bc2694be8113da7 80958	no	5
Warnings:					
Information:					
20	NPL Documents	Blancop38MAPKSignallingCascadesAncientRolesandNewFunctions.pdf	212665 9bda9194bca715813bb66cnc56fb372bb c71781	no	9
Warnings:					
Information:					
21	NPL Documents	BOLLAGETALRAFPATHWAY.pdf	580972 4b4c6a973cccb470d644811fc04d618f 2945	no	6
Warnings:					
Information:					
22	NPL Documents	CAMPBELLETAL.pdf	2424350 a9005795d543aa4007fnc14663d4b2ba97 1ed17	no	19
Warnings:					
Information:					
23	NPL Documents	CarterAntitumorEfficacyoftheOrallyActiveRAFKinaseInhibitor.pdf	201656 a9c11c26c600315d4c694b6ed1330b5c952 9181	no	2
Warnings:					
Information:					
24	NPL Documents	ChangBAY43-9006SorafenibInhibitsEctopicSCandOrthotopicGrowthofaMurine.pdf	73262 b4599634e662393827d61063921213bbf 208602	no	1
Warnings:					
Information:					
25	NPL Documents	ClarkSafetyandPharmacokineticsoftheDualActionRAFKinaseand.pdf	1034920 c2ed02ee4a6b12855ab1595d65c2702ba2d 442a1	no	9
Warnings:					
Information:					
26	NPL Documents	DansonImprovingOutcomesinAdvancedMalignantMelanoma.pdf	859338 9cc3dc7928f52a1f596d1118d4812a1659 3a	no	11
Warnings:					
Information:					
27	NPL Documents	DeGrendeleActivityoftheRAFKinaseInhibitorBAY43-9006inPatientswithAdvancedSolidTumors.pdf	222928 dfaa060b3acc0dd5ea69a0a754c997f5bae d972a	no	3

Warnings:					
Information:					
28	NPL Documents	DumasProtienKinaseInhibitorsFormtheUreaClass.pdf	750454 28122b0f96242ce5a7781094466404b8844918003	no	10
Warnings:					
Information:					
29	NPL Documents	DUMASETALRECENTDEVELOPMENTS.pdf	1504470 a7ed578f82b0b6e445cd8515c2cda9e2b13467	no	17
Warnings:					
Information:					
30	NPL Documents	DUMASJETALSYNTHESISANDPHARMACOLOGICAL.pdf	383855 2b8f8b9166e797db25a7e0d1bdc5dbcb38824e	no	4
Warnings:					
Information:					
31	NPL Documents	DumasETALDISCOVERYOFACLASSOF38KINASE.pdf	293780 0a4db26107483b2754c108b69082ec1444b9f4618f9	no	4
Warnings:					
Information:					
32	NPL Documents	EisenPhaseITrialofBAY43-9006SorafenibCombinedwithDacarbazineDTICinMetastaticMelanomaPatients.pdf	66103 1a2f856a0619b172b667761ba6e34778a857d	no	1
Warnings:					
Information:					
33	NPL Documents	EisenhauerImpactofNewNon-CytotoxicsintheTreatmentofOvarianCancer.pdf	512335 a86a091316a91d7b0a7a0b880a00735c95673	no	5
Warnings:					
Information:					
34	NPL Documents	EscudierRandomizedPhaseIIITrialoftheRafKinaseandVEGFRInhibitorSorafenib.pdf	71404 7518910a05577b13dc3c3b50b594045db5d138147	no	1
Warnings:					
Information:					
35	NPL Documents	FactsandComparisons1994edition.pdf	662046 7b0cd1b04c138101d220988f589cc251a32f4e132e	no	4
Warnings:					
Information:					
36	NPL Documents	Garcia-LopezNewRoutesfortheSynthesisofPyrrolo.pdf	370184 c1a552a8f06031da6512d7a5e49561703c8f1	no	5

Warnings:					
Information:					
37	NPL Documents	HansonInhibitorsOfp38KinaseInHepG2ConnectInhibitorsOfp38Kinase.pdf	49863 97525cc969703648A3b392f88c896cd38daf	no	1
Warnings:					
Information:					
38	NPL Documents	HeimAntitumorEffectandPotentialorReductioninCytotoxicDrugActivityinHumanColon.pdf	157173 7169f3e4d1dc079c36d324144c1488a6194b6e68a	no	2
Warnings:					
Information:					
39	NPL Documents	HOTTEETAL.pdf	393065 bd39d6a31730065af10db69f1dae4abdbd9f37a2	no	5
Warnings:					
Information:					
40	NPL Documents	HubbardOncogenicMutationsinB-RafSomeLossesYieldGains.pdf	318340 ae4600bd21651d408051accf988c627ac559323c	no	3
Warnings:					
Information:					
41	NPL Documents	KEMPTERETAL.pdf	1396625 8c3d918ab6c1894f8c291800469c99c27d62f304	no	20
Warnings:					
Information:					
42	NPL Documents	KHIREETAL.pdf	262018 408ca1abac2119213c21d1a948489926d0bcce4db	no	4
Warnings:					
Information:					
43	NPL Documents	LEEETAL.pdf	589793 79315a4885c24a64b95a2814280db76d497a2d68	no	7
Warnings:					
Information:					
44	NPL Documents	LOWRINGERETALDISCOVEROFSMALLMOLECULES.pdf	627223 8a5e8302b51c201bc26c47a6b6c92778b801d4af	no	10
Warnings:					
Information:					
45	NPL Documents	LowingeretalProteinKinaseInhibitorsFromTheUreaClass.pdf	148446 30c948a99d7db5597bb1f19a697857c40f3816c	no	1

Warnings:					
Information:					
46	NPL Documents	LYONSETAL.pdf	816218 Bee0Beb1c240da3dec3c172182969977a090813	no	8
Warnings:					
Information:					
47	NPL Documents	MadwedPharmacologicalEvaluationofBIRB796.pdf	77971 3c344521d14db7195378d058c8da55d3fb3827	no	1
Warnings:					
Information:					
48	NPL Documents	MOELLINGETAL.pdf	845713 d854d5f274e60f9c4dee04bac48e0b30958363	no	9
Warnings:					
Information:					
49	NPL Documents	MOOREETAL.pdf	576594 db64f71bec08411c7b7c9e73f962302bc13ce4dc	no	7
Warnings:					
Information:					
50	NPL Documents	MROSSETAL.pdf	187834 8364cdd2cc52755e1c37811c0f1e4836ad7aa3	no	2
Warnings:					
Information:					
51	NPL Documents	MURPHYETAL.pdf	71331 ewa09a67ae093a01c1038eab74af043c0efc0f16	no	1
Warnings:					
Information:					
52	NPL Documents	NickelCarboxylicAcidAnaloguesofSuraminPotentialFilaricides.pdf	415868 ee5136f9a683b837c08fdac3a271a0f030fb344	no	6
Warnings:					
Information:					
53	NPL Documents	PankaBAY43-9006InducesApoptosisinMelanomaCellLines.pdf	43543 a0f5e0fca0061c3061f6080bb7249a3898f900c	no	1
Warnings:					
Information:					
54	NPL Documents	WilhelmANovelDiphenylureaRafKinaseInhibitorRK1BlockstheRafMEKERKPathwayinTumorCells.pdf	52216 7c0cnd73df0a92931c101c3f5ab256cd0b7897db	no	1

Warnings:					
Information:					
55	NPL Documents	REDMANETAL.pdf	293632 a848894b0500125717a103d00155678e522c803	no	4
Warnings:					
Information:					
56	NPL Documents	ReganPyrazoleUrea-BasedInhibitorsofp38MAPKinaseFormLeadCompoundtoClinicalCandidate.pdf	1709151 bd0f3c6073fd0619186a7233d1014842b1b853	no	15
Warnings:					
Information:					
57	NPL Documents	RichlyAPhaseIClinicalandPharmacokineticStudyoftheRafKinaseInhibitorRKIBAY43-9006.pdf	243578 9818659724a81c539c6aef398c94ae4972a823	no	2
Warnings:					
Information:					
58	NPL Documents	RichlyResultsofaPhaseITrialofBAY43-9006inCombinationwithDoxorubicinin.pdf	139610 2fec20c5d8f1ba1b15266221b0a5c3f76498811	no	2
Warnings:					
Information:					
59	NPL Documents	RiedletalPotentRafKinaseInhibitorsfromtheDiphenyl.pdf	43951 5482a67d7acbf10a71951c23c8902ee8b534f5d2	no	1
Warnings:					
Information:					
60	NPL Documents	SiuPhaseIStudyofOralRaf1KinaseInhibitor.pdf	63765 1c1e419fb190b49ff6b8a67140ba5c85008c995	no	1
Warnings:					
Information:					
Total Files Size (in bytes):			87864277		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.